Trials / Terminated
TerminatedNCT03205046
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acalabrutinib | Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor. |
| DRUG | vistusertib | Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase |
Timeline
- Start date
- 2017-06-29
- Primary completion
- 2019-11-20
- Completion
- 2019-11-20
- First posted
- 2017-07-02
- Last updated
- 2021-01-06
- Results posted
- 2021-01-06
Locations
11 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03205046. Inclusion in this directory is not an endorsement.